Principal Financial Group Inc. Buys New Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Principal Financial Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,294 shares of the company’s stock, valued at approximately $267,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in YMAB. Massachusetts Financial Services Co. MA grew its holdings in shares of Y-mAbs Therapeutics by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after purchasing an additional 2,760 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. grew its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of Y-mAbs Therapeutics by 4.2% during the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after acquiring an additional 3,589 shares during the last quarter. Finally, FMR LLC increased its holdings in Y-mAbs Therapeutics by 23.1% during the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock worth $479,000 after purchasing an additional 6,822 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Trading Down 4.4 %

Shares of Y-mAbs Therapeutics stock opened at $7.81 on Tuesday. Y-mAbs Therapeutics, Inc. has a twelve month low of $6.92 and a twelve month high of $20.90. The stock has a market capitalization of $349.80 million, a price-to-earnings ratio of -14.46 and a beta of 0.69. The business’s 50 day simple moving average is $10.91 and its 200-day simple moving average is $12.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on YMAB. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target on the stock. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.